The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19

被引:21
|
作者
Yang, Rongrong [1 ]
Xiong, Yong [1 ]
Ke, Hengning [1 ]
Chen, Tielong [1 ]
Gao, Shicheng [1 ]
机构
[1] Wuhan Univ, Zhongnan Hosp, Dept Infect Dis, Donghu Rd 169, Wuhan 430071, Peoples R China
关键词
COVID-19; cytokine storm; methylprednisolone; prognosis; SARS-CoV-2; ACUTE RESPIRATORY SYNDROME; CLINICAL CHARACTERISTICS; CORTICOSTEROID TREATMENT; INFLUENZA; PNEUMONIA; MORTALITY; HYDROCORTISONE;
D O I
10.1111/eci.13412
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background COVID-19 is a public health emergency that is spreading worldwide and seriously affecting the global economy. Data on the effectiveness and safety of the use of methylprednisolone for patients with severe COVID-19 remain limited. Methods In this retrospective study, epidemiological, clinical, laboratory, treatment and outcomes data of hospitalized patients with severe COVID-19 in Zhongnan Hospital of Wuhan University from January 1 to 7 March 2020, were collected. Binary logistic regression model was used to analyse risk factors for disease progression from severe COVID-19 illness to critical illness. The effectiveness and safety of the use of methylprednisolone for patients with severe COVID-19 disease were evaluated. Results The results of the multivariate analysis from 175 patients with severe COVID-19 indicate that the use of methylprednisolone was a protective factor against disease progression from severe to critical illness(P < .001; OR: 0.054 95% CI: 0.017-0.173). Among patients with severe COVID-19 aged < 65 years, both the proportion of patients who progressed to critical illness (42.2% vs 90.0%,P = .000) and the mortality(6.7% vs 30.0%,P = .002) were lower for patients in methylprednisolone group, compared with those in the non-methylprednisolone group, whereas no statistical differences between the methylprednisolone group and the non-methylprednisolone group were found among patients with COVID-19 older than 65 years. Moreover, both the levels of CD4(+)T lymphocyte counts (646 vs 463/mu L,P = .007) and IL-6 (241.9 vs 82.8 pg/mL,P = .025) were higher among patients with severe COVID-19 aged < 65 years, compared with those patients >= 65 years old. Conclusion Data from the limited sample showed that the early use of low or medium doses of methylprednisolone has a positive effect for patients with severe COVID-19 younger than 65 years old, and excessive immune response and cytokine storm may be some of the reasons for the effectiveness.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] The role of methylprednisolone in severe COVID-19 patients: a meta-analysis
    Xu, Wanru
    Zeng, Yujun
    Han, Hedong
    Lv, Tangfeng
    Lin, Dang
    FRONTIERS IN MEDICINE, 2024, 11
  • [2] METHYLPREDNISOLONE COMPARED TO DEXAMETHASONE FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS
    Kim, Sarah
    Cho, Nam
    Tellez, Eglis
    Moussavi, Kayvan
    CRITICAL CARE MEDICINE, 2023, 51 (01) : 388 - 388
  • [3] Reduced Risk of Progression from Non-Severe to Severe COVID-19 in Hospitalized Dialysis Patients by Full COVID-19 Vaccination
    Ichii, Mitsuru
    Kurajoh, Masafumi
    Okute, Yujiro
    Ihara, Yasutaka
    Imai, Takumi
    Morioka, Tomoaki
    Mori, Katsuhito
    Shoji, Tetsuo
    Tsujimoto, Yoshihiro
    Ubai, Takanobu
    Emoto, Masanori
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (21)
  • [4] Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease
    Hoertel, Nicolas
    Boulware, David R.
    Sanchez-Rico, Marina
    Burgun, Anita
    Limosin, Frederic
    JAMA NETWORK OPEN, 2022, 5 (11) : e2242140
  • [5] Predictive factors for disease progression in moderate to severe COVID-19 patients
    Boubaker, Nouha
    Louhaichi, Sabrine
    Khalfallah, Ikbel
    Belkhir, Safa
    Ferchichi, Mariem
    Ammar, Jamel
    Hamdi, Besma
    Hamzaoui, Agnes
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [6] Prediction of COVID-19 Patients at High Risk of Progression to Severe Disease
    Dai, Zhenyu
    Zeng, Dong
    Cui, Dawei
    Wang, Dawei
    Feng, Yanling
    Shi, Yuhan
    Zhao, Liangping
    Xu, Jingjing
    Guo, Wenjuan
    Yang, Yuexiang
    Zhao, Xinguo
    Li, Duoduo
    Zheng, Ye
    Wang, Ao
    Wu, Minmin
    Song, Shu
    Lu, Hongzhou
    FRONTIERS IN PUBLIC HEALTH, 2020, 8
  • [7] High doses of methylprednisolone in patients with severe COVID-19 infection
    Farhan, Ahmed
    Kanwal, Saira
    Ahmad, Arslan
    Ali, Syed Muneeb
    Khan, Naveed Ullah
    ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, 2023, 14 (11):
  • [8] Efficacy of additional hemoperfusion in hospitalized patients with severe to critical COVID-19 disease
    Chiewroongroj, Supattra
    Ratanarat, Ranistha
    Naorungroj, Thummaporn
    Teeratakulpisarn, Napassorn
    Theeragul, Suapa
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [9] Vitamin D Status and Severe COVID-19 Disease Outcomes in Hospitalized Patients
    Pecina, Jennifer L.
    Merry, Stephen P.
    Park, John G.
    Thacher, Tom D.
    JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH, 2021, 12
  • [10] The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19
    Enric Monreal
    Susana Sainz de la Maza
    Jose Ignacio Fernández-Velasco
    Elena Natera-Villalba
    Claudia Geraldine Rita
    Fernando Rodríguez-Jorge
    Álvaro Beltrán-Corbellini
    Ignacio Iturrieta-Zuazo
    Enrique Rodríguez de Santiago
    Mercedes Espiño
    Ana de Andrés
    Jesús Fortún
    Esther Barbero
    Mónica Vázquez
    Milagros Fernández Lucas
    Luis Manzano
    Beatriz Montero-Errasquín
    Lucienne Costa-Frossard
    Jaime Masjuan
    Luisa María Villar
    Journal of Clinical Immunology, 2021, 41 : 315 - 323